MCID: CNR002
MIFTS: 68

Cone-Rod Dystrophy malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases

Aliases & Classifications for Cone-Rod Dystrophy

About this section

Aliases & Descriptions for Cone-Rod Dystrophy:

Name: Cone-Rod Dystrophy 52 35 11 48 24 25 12 50 13
Cone-Rod Dystrophy 2 48 24 70 27 68
Cord2 48 24 70
Cone-Rod Retinal Dystrophy 2 48 70
Cone-Rod Retinal Dystrophy-2 52 12
Tapetoretinal Degeneration 25 27
Cone-Rod Retinal Dystrophy 11 25
Cone-Rod Dystrophy 5 11 68
Crd2 48 70
Progressive Cone-Rod Dystrophy 68
 
Retinal Cone-Rod Dystrophy 2 48
Retinal Cone-Rod Dystrophy 25
Retinitis Pigmentosa 2 68
Cone-Rod Degeneration 25
Retinitis Pigmentosa 68
Cone Rod Dystrophy 27
Rcrd2 48
Cord 25
Crd 25

Characteristics:

HPO:

64
cone-rod dystrophy:
Inheritance: autosomal dominant inheritance

Classifications:



External Ids:

OMIM52 120970
Disease Ontology11 DOID:0050572
ICD1030 H35.5, G95.2
MeSH39 D012174

Summaries for Cone-Rod Dystrophy

About this section
OMIM:52 Cone-rod dystrophy (CORD) characteristically leads to early impairment of vision. An initial loss of color vision and... (120970) more...

MalaCards based summary: Cone-Rod Dystrophy, also known as cone-rod dystrophy 2, is related to spondylometaphyseal dysplasia with cone-rod dystrophy and cone-rod dystrophy 3, and has symptoms including photophobia, nyctalopia and abnormality of retinal pigmentation. An important gene associated with Cone-Rod Dystrophy is CRX (Cone-Rod Homeobox), and among its related pathways are the visual cycle I (vertebrates) and Visual Cycle in Retinal Rods. Affiliated tissues include retina, eye and bone, and related mouse phenotypes are Decreased shRNA abundance (Z-score < -2) and cardiovascular system.

Disease Ontology:11 A retinal degeneration that characterized by progressive deterioration of the cone and rod photoreceptor cells.

Genetics Home Reference:25 Cone-rod dystrophy is a group of related eye disorders that causes vision loss, which becomes more severe over time. These disorders affect the retina, which is the layer of light-sensitive tissue at the back of the eye. In people with cone-rod dystrophy, vision loss occurs as the light-sensing cells of the retina gradually deteriorate.

NIH Rare Diseases:48 Cone-rod dystrophies (CRDs) are a group of inherited eye disorders that affect both the cone and rod cells of the retina (photosenstitive receptor cells). In contrast to rod-cone dystrophies, individuals experience deterioration of the cone cells more severely than the rod cells. Initial signs and symptoms typically include decreased visual acuity when looking straight ahead (central vision loss); loss of color perception; and an abnormal sensitivity to light (photophobia). These signs are usually followed by progressive loss of peripheral vision and night blindness. Most cases occur due to mutations in any one of several genes, and CRDs can be inherited as autosomal recessive, autosomal dominant, X-linked or mitochondrial (maternally-inherited) traits. CRDs are usually non-syndromic, but they may also be part of several syndromes. Currently, there is no therapy that stops progression of the disease or restores vision; management aims at slowing the process, treating complications and helping individuals cope with the social and psychological impact of blindness. Last updated: 5/23/2011

UniProtKB/Swiss-Prot:70 Cone-rod dystrophy 2: An inherited retinal dystrophy characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa.

Related Diseases for Cone-Rod Dystrophy

About this section

Diseases related to Cone-Rod Dystrophy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 255)
idRelated DiseaseScoreTop Affiliating Genes
1spondylometaphyseal dysplasia with cone-rod dystrophy12.6
2cone-rod dystrophy 312.6
3cone-rod dystrophy 912.6
4cone-rod dystrophy 712.6
5cone-rod dystrophy, x-linked, 112.5
6cone-rod dystrophy 1612.5
7cone-rod dystrophy 512.5
8cone-rod dystrophy 2012.5
9cone-rod dystrophy 1212.5
10cone-rod dystrophy 1512.5
11cone-rod dystrophy 1312.5
12cone-rod dystrophy 1112.5
13cone-rod dystrophy 1812.4
14cone-rod dystrophy 1912.4
15cone-rod dystrophy 1012.4
16cone-rod dystrophy 612.4
17cone-rod dystrophy 2112.4
18spinal cord injury12.3
19cone-rod dystrophy 812.2
20cone-rod dystrophy 1712.2
21cone-rod dystrophy 112.2
22leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation12.2
23spinal cord disease12.2
24jalili syndrome12.2
25sex cord-gonadal stromal tumor12.2
26cone-rod dystrophy x-linked 212.1
27cone-rod dystrophy 412.1
28cone-rod dystrophy, aipl1-related12.1
29cone-rod dystrophy, prph2-related12.1
30cone-rod dystrophy, unc119-related12.1
31tethered spinal cord syndrome12.1
32spinal cord ependymoma12.0
33spinal cord glioma12.0
34spinal cord infarction12.0
35spermatic cord torsion12.0
36spinal cord lymphoma12.0
37tapetoretinal degeneration with ataxia12.0
38umbilical cord ulceration and intestinal atresia12.0
39central cord syndrome12.0
40cone-rod dystropy, x-linked, 312.0
41hypomyelination with brainstem and spinal cord involvement and leg spasticity12.0
42spinal cord lipoma12.0
43cerebellar hypoplasia tapetoretinal degeneration12.0
44charcot-marie-tooth disease, axonal, with vocal cord paresis11.9
45central cervical cord syndrome11.9
46spermatic cord cancer11.9
47cone dystrophy-311.9
48spinal cord astrocytoma11.9
49spinal cord melanoma11.8
50spinal cord oligodendroglioma11.8

Graphical network of the top 20 diseases related to Cone-Rod Dystrophy:



Diseases related to cone-rod dystrophy

Symptoms & Phenotypes for Cone-Rod Dystrophy

About this section

Symptoms by clinical synopsis from OMIM:

120970

Clinical features from OMIM:

120970

Human phenotypes related to Cone-Rod Dystrophy:

 64 (show all 11)
id Description HPO Frequency HPO Source Accession
1 photophobia64 hallmark (90%) HP:0000613
2 nyctalopia64 hallmark (90%) HP:0000662
3 abnormality of retinal pigmentation64 hallmark (90%) HP:0007703
4 abnormality of color vision64 typical (50%) HP:0000551
5 visual impairment64 occasional (7.5%) HP:0000505
6 chorioretinal atrophy64 HP:0000533
7 cone/cone-rod dystrophy64 HP:0000548
8 blindness64 HP:0000618
9 constriction of peripheral visual field64 HP:0001133
10 reduced visual acuity64 HP:0007663
11 peripheral visual field loss64 HP:0007994

UMLS symptoms related to Cone-Rod Dystrophy:


pigmented retinopathy nos

GenomeRNAi Phenotypes related to Cone-Rod Dystrophy according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00366-A-5811.1EYS, PDE6B, TOPORS

MGI Mouse Phenotypes related to Cone-Rod Dystrophy according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538510.9ABCA4, CRX, PDE6B, PROM1, PRPH2, RHO
2MP:000118610.7ABCA4, BEST1, C2orf71, CRB1, CRX, PDE6B
3MP:000363110.5ABCA4, C2orf71, CRB1, CRX, PDE6B, PROM1
4MP:00053919.6ABCA4, BEST1, C2orf71, CRB1, CRX, PDE6B

Drugs & Therapeutics for Cone-Rod Dystrophy

About this section

Drugs for Cone-Rod Dystrophy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 110)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Vitamin Aapproved, nutraceutical, vet_approvedPhase 3, Phase 146811103-57-4, 68-26-8445354
Synonyms:
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
11103-57-4
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
A-Mulsal
A-Sol
A-Vi-Pel
A-Vitan
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
AR-1L3057
ATAV
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
All Trans Retinol
All-trans retinol
All-trans-Retinol
Alphalin
Alphasterol
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol A Parenteral
Aquasynth
Atars
Avibon
Avita
Avitol
Axerol
Axerophthol
Axerophtholum
BIDD:PXR0102
BRN 0403040
Bentavit A
Biosterol
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
CID445354
Chocola A
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
HMS1921B04
HMS2092L13
HMS501I08
HSDB 815
Hi-A-Vita
Homagenets Aoral
Homagenets aorl
Hydrovit A
IDI1_000486
LMPR01090001
LPK
LS-1578
Lard Factor
M.V.C. 9+3
M.V.I.-12
 
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
NSC 122759
NSC122759
Nio-A-Let
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
Retinol
Retinol [INN:BAN]
Retinol solution
Retinol, all-trans- (8CI)
Retinol-(cellular-retinol-binding-protein)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
SMP2_000102
SMR000112036
SPECTRUM1501203
ST057232
Sehkraft A
Solu-A
Spectrum5_000993
Spectrum5_001997
Super A
Testavol
Testavol S
Thalasphere
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-Alpha
Vi-Dom-A
Vi-a
Vio-A
Vitamin A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin A alcohol (VAN)
Vitamin A cryst
Vitamin A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin- A
Vitamin- A alcohol
Vitamin- A alcohol solution
Vitamin- A1
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
Wachstumsvitamin
ZINC03831417
Zinosan N
[11,12-3H]-Retinol
alin
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-Retinol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
all-trans-retinol
all-trans-retinyl alcohol
all-trans-vitamin A alcohol
b-Retinol
beta-Retinol
retinol
tROL
trans-Retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
trans-retinol
2
Luteinapproved, nutraceuticalPhase 3, Phase 1, Phase 269127-40-26433159, 5368396
Synonyms:
(3R,3'R)-beta,beta-Carotene-3,3'-Diol, Lutein
(3R,3'R,6'R)-Lutein
(3R,3'R,6S)-4,5-Didehydro-5,6-Dihydro-beta,beta-Carotene-3,3'-Diol
3,3'-Dihydroxy-alpha-carotene
4,5-Didehydro-5,6-dihydro-beta,beta-carotene-3,3'-diol
All-trans-(+)-Xanthophyll
All-trans-Lutein
All-trans-Xanthophyll
 
Bo-Xan
Lutein
Lutein ester
Luteine
Phylloxanthin
Vegetable lutein
Vegetable luteol
beta,epsilon-Carotene-3,3'-diol
trans-Lutein
3
Vitamin Eapproved, nutraceutical, vet_approvedPhase 340659-02-914985
Synonyms:
(+)-a-Tocopherol
(+)-alpha-Tocopherol
(+)-α-tocopherol
(2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL
(2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol
(2R,4'R,8'R)-a-Tocopherol
(2R,4'R,8'R)-alpha-Tocopherol
(2R,4'R,8'R)-α-tocopherol
(R,R,R)-a-Tocopherol
(R,R,R)-alpha-Tocopherol
(R,R,R)-α-tocopherol
5,7,8-Trimethyltocol
5,7,8-trimethyltocol
Amino-Opti-E
Aquasol E
D-alpha-Tocopherol
Daltose
Denamone
E-200 I.U. Softgels
 
E-Complex-600
E-Ferol
E-Vitamin succinate
Eprolin
Gordo-Vite E
Phytogermin
Phytogermine
RRR-alpha-tocopherol
RRR-alpha-tocopheryl
Tocopherol
Vitamin E
Vitamin Ea
Vitamin Plus E Softgells
Vitec
a-D-Tocopherol
a-Tocopherol
alpha-Tocopherol
alpha-delta-Tocopherol
alpha-tocopherol
d-α-tocopherol
delta-alpha-Tocopherol
4vitamin dPhase 31653
5VitaminsPhase 3, Phase 2, Phase 1, Early Phase 15095
6TocopherolsPhase 3406
7TocotrienolsPhase 3402
8Antihypertensive AgentsPhase 3, Phase 1, Phase 24095
9Trace ElementsPhase 3, Phase 2, Phase 1, Early Phase 15802
10Bone Density Conservation AgentsPhase 33266
11MicronutrientsPhase 3, Phase 2, Phase 1, Early Phase 15802
12Protective AgentsPhase 3, Phase 2, Phase 17190
13Retinol palmitatePhase 3, Phase 1468
14AntioxidantsPhase 3, Phase 2, Phase 12928
15CarotenoidsPhase 2, Phase 3, Phase 1151
16Isopropyl unoprostonePhase 32
17retinolNutraceuticalPhase 3, Phase 1468
18TocopherolNutraceuticalPhase 3406
19TocotrienolNutraceuticalPhase 3402
20Beta CaroteneNutraceuticalPhase 2, Phase 3, Phase 167
21
Povidone-iodineapprovedPhase 2, Phase 115525655-41-8
Synonyms:
 
Betadine
22
Ciprofloxacinapproved, investigationalPhase 2, Phase 122985721-33-12764
Synonyms:
1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperzinyl)-3-quinolinecarboxylic acid HCl H2O
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
17850_FLUKA
3-Quinolinecarboxylic acid,1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)
33434_FLUKA
33434_RIEDEL
85721-33-1
AC-7613
AC1L1EEW
AKOS000269653
ARONIS020379
Alcon Cilox
BAS 06989041
BAY q 3939
BAY-Q-3939
BAYQ3939
BIDD:GT0205
BPBio1_000140
BRD-K04804440-311-02-3
BRN 3568352
BSPBio_000126
BSPBio_003344
Bacquinor
Baflox
Bay o 9867
Bay o 9867 (*Hydrochloride*)
Bay-09867
Baycip
Bernoflox
Bi-Cipro
Bio-0540
C05349
C17H18FN3O3
CAS-93107-08-5
CBMicro_048498
CCRIS 5241
CHEBI:100241
CHEMBL8
CID2764
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
CPF
CPFX
CRL-1605 & Ciprofloxacin
Ciflox
Cifloxin
Cilab
Ciloxan
Ciloxan (*Hydrochloride*)
Ciplus
Ciprecu
Ciprinol
Cipro
Cipro (*Hydrochloride*)
Cipro (TN)
Cipro I.V.
Cipro IV
Cipro XL
Cipro XR
Ciprobay
Ciprobay Uro
Ciprocinol
Ciprodar
Ciproflox
Ciprofloxacin
Ciprofloxacin (JAN/USP/INN)
Ciprofloxacin HCl
Ciprofloxacin Hydrchloride
Ciprofloxacin [USAN:INN:BAN]
Ciprofloxacin dihydrochloride
Ciprofloxacin hydrochloride
Ciprofloxacin monohydrochloride
Ciprofloxacina
Ciprofloxacine
Ciprofloxacine [INN-French]
Ciprofloxacino
 
Ciprofloxacino [INN-Spanish]
Ciprofloxacinum
Ciprofloxacinum [INN-Latin]
Ciprogis
Ciprolin
Ciprolon
Cipromycin
Ciproquinol
Ciprowin
Ciproxan
Ciproxin
Ciproxina
Ciproxine
Ciriax
Citopcin
Cixan
Corsacin
Cycin
Cyprobay
D00186
DB00537
DivK1c_000095
Eni
Fimoflox
Flociprin
Floxin
HMS1922E18
HMS2090O07
HMS2093I03
HMS500E17
HSDB 6987
IDI1_000095
Ipiflox
Italnik
KBio1_000095
KBio2_000642
KBio2_003210
KBio2_005778
KBio3_002846
KBioGR_001567
KBioSS_000642
LS-141563
Liposomal-ciprofloxacin
Loxan
MLS001336035
MolPort-000-819-654
NCGC00016959-01
NCGC00095058-01
NCGC00095058-02
NCGC00178128-01
NINDS_000095
NSC620634
Ocuflox
Oprea1_008239
Oprea1_313572
Prestwick0_000113
Prestwick1_000113
Prestwick2_000113
Prestwick3_000113
Probiox
Proflaxin
Proflox
Proksi 250
Proksi 500
Proquin XR
Quinolid
Quintor
Rancif
Roxytal
SMP1_000125
SMR000471901
SPBio_001474
SPBio_002065
SPECTRUM1503614
STK021082
Septicide
Sophixin Ofteno
Spectrum2_001567
Spectrum3_001872
Spectrum4_000874
Spectrum5_001089
Spectrum_000162
Spitacin
Superocin
UNII-5E8K9I0O4U
Unex
Velomonit
Zumaflox
ciprofloxacin
nchembio820-comp1
23
Minocyclineapproved, investigationalPhase 1, Phase 222410118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
HMS2090D03
HSDB 3130
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
24
Valproic Acidapproved, investigationalPhase 232299-66-13121
Synonyms:
(N-C3H7)2CHCOOH
(S)-2-propyl-4-pentanoate
(S)-2-propyl-4-pentanoic acid
2 PP (base)
2-N-Propyl-N-valeric acid
2-Propyl-Pentanoate
2-Propyl-Pentanoic acid
2-Propylpentanoate
2-Propylpentanoic Acid
2-Propylpentanoic acid
2-Propylvaleric Acid
2-Propylvaleric acid
2-n-Propyl-n-valeric acid
2-n-propyl-n-valeric acid
2-propyl-pentanoic acid
2-propylvaleric acid
4-Heptanecarboxylic acid
4-heptanecarboxylic acid
76584-70-8 (hydrochloride salt (2:1))
99-66-1
AC1L1F7T
AC1Q2ULA
AI3-10500
APO-divalproex
Abbott 44090
Acide valproique
Acide valproique [INN-French]
Acide valproique [inn-french]
Acido valproico
Acido valproico [INN-Spanish]
Acido valproico [inn-spanish]
Acidum valproicum
Acidum valproicum [INN-Latin]
Acidum valproicum [inn-latin]
Alti-Valproic
Alti-valproic
Apo-valproic
Apo-valproic syrup
Avugane
BIDD:GT0858
BRN 1750447
Baceca
C07185
CHEBI:39867
CHEMBL109
CID3121
CPD000499581
Convulex
Convulsofin
D00399
DB00313
DOM-divalproex
DOM-valproic
DOM-valproic acid E.C.
DPA
Delepsine
Depacon
Depakene
Depakene (TN)
Depakin
Depakin chrono
Depakine
Depakine chrono
Depakote
Depakote (TM)
Deproic
Di-N-propylacetic acid
Di-N-propylessigsaure
Di-N-propylessigsaure [german]
Di-n-propylacetic acid
Di-n-propylessigsaeure
Di-n-propylessigsaure
Di-n-propylessigsaure [German]
Di-n-propylessigsäure
Dipropyl Acetate
Dipropylacetate
Dipropylacetic acid
DivK1c_000273
Divalproex
Dom-Valproic
Dom-valproate
Dom-valproic acid
Dom-valproic acid syrup
EINECS 202-777-3
Epiject I.V.
Epilex
Epilim
Epival
Epival er
Ergenyl
G2M-777
Gen-divalproex
HMS2089J06
HSDB 3582
I04-0211
InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)
KBio1_000273
KBio2_001001
KBio2_002277
KBio2_003569
KBio2_004845
 
KBio2_006137
KBio2_007413
KBio3_002626
KBio3_002757
KBioGR_000871
KBioGR_002277
KBioSS_001001
KBioSS_002278
Kyselina 2-propylvalerova
Kyselina 2-propylvalerova [Czech]
LS-161170
LS-2068
MLS001076682
MLS001335927
MLS001335928
MLS002415770
Med Valproic
Med valproic
MolPort-001-791-895
Mylproin
Myproate
Myproic Acid
Myproic acid
N-DPA
N-Dipropylacetic acid
NCGC00091149-01
NCGC00091149-02
NCGC00091149-03
NCGC00091149-04
NINDS_000273
NSC 93819
NSC93819
Novo-Valproic
Novo-Valproic - ECC
Novo-divalproex
Novo-valproic
Novo-valproic soft gel cap
Nu-Valproic
Nu-valproic
P0823
P6273_SIGMA
PEAC
PHL-valproate
PHL-valproic acid
PHL-valproic acid E.C.
PMS-Divalproex
PMS-Valproic Acid
PMS-valproate
PMS-valproic acid
PMS-valproic acid E.C.
Penta-Valproic
Penta-valproic
Propylvaleric acid
Ratio-Valproic - ECC
S(-)-4-En-valproate
S(-)-4-En-valproic acid
S-2-N-Propyl-4-pentenoate
S-2-N-Propyl-4-pentenoic acid
SAM002564230
SBB065764
SMR000499581
SPBio_000912
Sandoz valproic
Savicol
Semisodium Valproate
Sodium hydrogen divalproate
Spectrum2_000946
Spectrum3_001733
Spectrum4_000376
Spectrum_000521
Sprinkle
Stavzor
UNII-614OI1Z5WI
VALPROIC ACID
VPA
Valcote
Valparin
Valproate
Valproate semisodique [French]
Valproate semisodium
Valproato semisodico [Spanish]
Valproatum seminatricum [Latin]
Valproic Acid, Sodium Salt (2:1)
Valproic acid
Valproic acid (USP)
Valproic acid USP
Valproic acid USP24
Valproic acid [USAN:INN:BAN]
Valproic acid [usan:ban:inn]
Valproinsaeure
Valproinsäure
Vupral
WLN: QVY3 & 3
acide valproïque
acidum valproicum
di-n-propylacetic acid
n-DPA
n-Dipropylacetic acid
nchembio.79-comp4
nchembio815-comp21
valproate
valproic acid
ácido valproico
25
DopamineapprovedPhase 2375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
26
LevodopaapprovedPhase 238859-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine
27
CarbidopaapprovedPhase 217728860-95-934359, 38101
Synonyms:
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid
(-)-L-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid monohydrate
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid--water (1/1)
(S)-(-)-carbidopa
(S)-(-)-carbidopa hydrate
(S)-(−)-carbidopa
(S)-alpha--Hydrazino-3,4-dihydroxy-alpha--methyl-benzenepropanoic acid monohydrate
(S)-carbidopa
(S)-carbidopa hydrate
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid
(alphaS)-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate
(αS)-α-hydrazino-3,4-dihydroxy-α-methylbenzenepropanoic acid
27925-91-3
28860-95-9
31823-41-3
38821-49-7
AC-1676
AC1L1RFR
AC1L1Z32
AC1Q5QGW
Atamet
BB_SC-5095
Benzenepropanoic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate, (S)
C-126
C-DOPA
C126_SIGMA
C1335_SIGMA
CCRIS 5093
CHEBI:3395
CHEBI:39585
CHEMBL1200748
CHEMBL1201236
CID34359
CID38101
CPD-11550
Carbidopa (anhydrous)
Carbidopa Anhydrous
Carbidopa Monohydrate
Carbidopa [USAN:INN:BAN]
Carbidopa anhydrous
Carbidopa hydrate
Carbidopa, (S)-Isomer
Carbidopa, Entacapone, & Levodopa
Carbidopa-1-wasser
 
Carbidopum
Carbidopum [INN-Latin]
DB00190
EINECS 249-271-9
EU-0100382
HMS2089B12
Hadrazino-alpha-methyldopa
Hydrocinnamic acid, (-)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, monohydrate
KINSON, 3-(3,4-DIHYDROXY-PHENYL)-2-HYDRAZINO-2-METHYL-PROPIONIC ACID
L-3-(3,4-Dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-3-(3,4-dihydroxyphenyl)-2-methyl-2-hydrazinopropionic acid
L-alpha-(3,4-dihydroxybenzyl)-alpha-hydrazinopropionic acid monohydrate
L-alpha-Methyl-alpha-hydrazino-beta-(3,4-dihydroxyphenylpropionic acid
L-alpha-Methyl-beta-(3,4-dihydroxyphenyl)-alpha-hydrazinopropionic acid
L-alpha-Methyldopahydrazine
L-α-methyldopahydrazine
LS-77199
Lodosin
Lodosyn
Lodosyn, Carbidopa
Lopac0_000382
MK 486
MK-485
MK-486
MLS000069628
MLS002207014
Methyldopahydrazine
MolPort-003-940-629
MolPort-005-934-181
N-Aminomethyldopa
NCGC00024596-01
NCGC00024596-03
NCGC00024596-05
NCGC00024596-06
S(-)-CARBIDOPA
S(-)-alpha-Hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate
S-(-)-Carbidopa
S-(-)-alpha-Hydrazino-3,4-dihydroxy-2-methylbenzenepropanoic acid
S1891_Selleck
SMP1_000057
SMR000058235
ST055523
Stalevo
Tocris-0455
UNII-KR87B45RGH
UNII-MNX7R8C5VO
alpha-Hydrazino-alpha-methyl-beta-(3,4-dihydroxyphenyl)propionic acid
alpha-Methyldopahydrazine
carbidopa
carbidopum monohydricum
28
EphedrineapprovedPhase 1, Phase 2606299-42-39294
Synonyms:
( )-Pseudoephedrine
(+)-Ephedrin
(+)-Ephedrine
(+)-Pseudoephedrine
(+)-psi-Ephedrine
(+)-threo-Ephedrine
(+-)-Ephedrine
(-)-Ephedrine
(-)-Pseudoephedrine
(-)-psi-Ephedrine
(-)-threo-Ephedrine
(1R,2R)-Ephedrine
(1R,2S)-1-Phenyl-1-hydroxy-2-methylaminopropane
(1S,2R)-Ephedrine
(L)-EPHEDRINE
--EPHEDRINE
1-EPHEDRINE
1-Sedrin
134910_ALDRICH
287636_ALDRICH
287644_ALDRICH
299-42-3
304-87-0
30987-59-8
321-96-0
321-97-1
321-98-2
37577-31-4
38732-95-5
45261_FLUKA
4607-45-8
50-98-6
50906-05-3
53214-57-6
649031_ALDRICH
6912-63-6
7009-81-6
90-82-4
968-63-8
AC-20231
AC-20292
AC1L1JGK
AC1L1NUA
AC1L1RFA
AC1L1SR1
AC1L1T31
AC1L1Y3M
AC1O8JUO
AC1Q3XJE
AC1Q3XJM
AC1Q3XJN
AC1Q59F5
AC1Q7701
AI3-02761
AKOS000268842
AR-1A0126
AR-1I7143
Acunaso
Acunaso (TN)
Afrinol
Ambap299-42-3
BIDD:GT0817
BRN 3197916
BRN 4231286
BSPBio_001946
BSPBio_001968
BSPBio_003261
Benylin Decongestant
Besan
Biophedrin
C01575
C02765
C10H15NO
CHEBI:15407
CHEBI:51209
CHEMBL1590
CHEMBL211456
CHEMBL357080
CID11972440
CID5032
CID62946
CID6710657
CID7028
CID8650
CID9294
CID9457
CPD-9954
CPDD 0049
Cenafed
D00124
D08449
DB00852
DB01364
Decofed
DivK1c_000181
DivK1c_000451
DivK1c_000461
Drixoral N.D.
EINECS 202-017-0
EINECS 202-018-6
EINECS 206-080-5
EINECS 206-292-8
EINECS 206-293-3
Eciphin
Efedrin
Efidac/24
Eltor 120
Ephedral
Ephedremal
Ephedrin
Ephedrine
Ephedrine (TN)
Ephedrine (USP)
Ephedrine [USAN:BAN]
Ephedrine l-form
Ephedrital
Ephedrol
Ephedrosan
Ephedrotal
Ephedsol
Ephendronal
Ephoxamin
Fedrin
Genaphed
HSDB 3072
HSDB 3177
I-Sedrin
I01-3584
I01-8925
I01-8928
 
IDI1_000181
IDI1_000451
IDI1_000461
Isoephedrine
Jsp005664
KBio1_000181
KBio1_000451
KBio1_000461
KBio2_001358
KBio2_001500
KBio2_003926
KBio2_004068
KBio2_006494
KBio2_006636
KBio3_001188
KBio3_001446
KBio3_002762
KBioGR_001013
KBioGR_001763
KBioSS_001358
KBioSS_001500
KST-1A9168
Kratedyn
L(+)-psi-Ephedrine
L(-)-Ephedrine
L-(+)-Ephedrine
L-(-)-Ephedrine
L-Ephedrine
L-erythro-2-(Methylamino)-1-phenylpropan-1-ol
L000968
LS-125921
LS-125922
LS-43083
LS-63961
LS-63962
LS-63963
LS-63964
Lexofedrin
Lopac-E-3250
Lopac0_000501
MLS000069657
Manadrin
Mandrin
Maxenal
MolPort-001-684-474
MolPort-001-684-477
MolPort-001-684-478
MolPort-001-684-479
MolPort-001-769-085
Myfedrine
NCGC00015408-01
NCGC00015408-02
NCGC00162174-01
NCGC00178180-01
NCGC00178889-01
NCI-C55652
NCI60_002955
NINDS_000181
NINDS_000451
NINDS_000461
NSC 165609
NSC 170951
NSC 8971
NSC165609
NSC170951
NSC8971
Nasol
Neodurasina
Neodurasina (TN)
Oprea1_287330
PDSP1_000168
PDSP1_001106
PDSP1_001343
PDSP1_001345
PDSP1_001346
PDSP1_001347
PDSP2_000167
PDSP2_001090
PDSP2_001327
PDSP2_001329
PDSP2_001330
PDSP2_001331
PSEUDOEPHEDRINE
Pedia Care
Pseudo
Pseudo 60's
Pseudo-12
Pseudoefedrina
Pseudoephedrine (D)
Pseudoephedrinum
Psi-ephedrin
Psi-ephedrine
Robidrine
SMR000059174
SPBio_000214
SPBio_001365
SPBio_001377
ST023802
STK367993
STOCK1N-42675
Sanedrine
Spectrum2_000137
Spectrum2_001303
Spectrum2_001309
Spectrum3_000414
Spectrum3_000563
Spectrum3_001771
Spectrum4_000497
Spectrum4_001162
Spectrum5_000650
Spectrum5_000879
Spectrum5_001106
Spectrum_000878
Spectrum_001020
Sudafed
Sudafed Decongestant
UNII-03VRY66076
UNII-7CUC9DDI9F
UNII-GN83C131XS
Vencipon
WLN: QYR & Y1 & M1
WLN: QYR&Y1&M1
Zephrol
d-Ephedrine
d-Isoephedrine
d-Pseudoephedrine
d-psi-Ephedrine
l-Ephedrine
l-Pseudoephedrine
racephedrine
trans-Ephedrine
29
AdapaleneapprovedPhase 1, Phase 276106685-40-960164
Synonyms:
106685-40-9
6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid
6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid
6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid
AC-1974
AC1L1SOH
AC1Q5USH
ADAPALENE
AKOS005145841
Adaferin
Adapalene (JAN/USAN/INN)
Adapalene [USAN:BAN:INN]
Adapaleno
Adapaleno [INN-Spanish]
Adapalenum
Adapalenum [INN-Latin]
Ambap106685-40-9
BIDD:GT0264
C28H28O3
CD 271
CD-271
CD271
 
CHEBI:217732
CHEBI:31174
CHEMBL1265
CHEMBL76401
CID60164
CPD000466349
D01112
DB00210
Differin
Differin (TN)
Differin, Adapalene
Differine
I06-0642
KS-1196
LS-172017
MLS000759463
MolPort-003-986-211
MolPort-006-823-940
NCGC00164617-01
S1276_Selleck
SAM001246663
SMR000466349
TL8000241
UNII-1L4806J2QF
30
PseudoephedrineapprovedPhase 1, Phase 260690-82-47028
Synonyms:
( )-Pseudoephedrine
(+) threo-2-(methylamino)-1-phenyl-1-propanol
(+)-(1S,2S)-Pseudoephedrine
(+)-Pseudoephedrine
(+)-psi-Ephedrine
(+)-threo-Ephedrine
(1S,2S)-(+)-Pseudoephedrine
(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol
(1S,2S)-2-Methylamino-1-phenyl-1-propanol
(1S,2S)-Pseudoephedrine
(1S,2S)-Pseudoephedrine, polymer-bound
1-Ephedrine
2-(Methylamino)-1-phenyl-1-propanol
287636_ALDRICH
304-87-0
30987-59-8
37577-31-4
649031_ALDRICH
90-82-4
AC-20292
AC1L1NUA
Acunaso
Acunaso (TN)
Afrinol
BIDD:GT0817
BRD-K84175871-003-02-2
BSPBio_003261
Balminil Decongestant Syrup
Benylin Decongestant
Benzenemethanol, alpha-((1S)-1-(methylamino)ethyl)-, (alpha-S)- (9CI)
Besan
C02765
C10H15NO
CHEBI:51209
CHEMBL1590
CID7028
CPD-9954
Cenafed
D-Isoephedrine
D-Pseudoephedrine
D-Pseudoephedrine base
D-Psi-2-Methylamino-1-phenyl-1-propanol
D-Psi-Ephedrine
D08449
DB00852
Decofed
Dimetapp Decongestant
Dimetapp Decongestant Pediatric Drops
DivK1c_000451
Drixoral N.D.
Drixoral Nasal Decongestant
EINECS 202-018-6
Efidac 24 Pseudoephedrine Hcl
Efidac/24
Eltor 120
Ephedrine
Genaphed
HSDB 3177
I01-8928
IDI1_000451
Isoephedrine
KBio1_000451
 
KBio2_001358
KBio2_003926
KBio2_006494
KBio3_002762
KBioGR_001763
KBioSS_001358
L(+)-Psi-Ephedrine
L(+)-psi-Ephedrine
L-(+)-Pseudoephedrine
LS-125922
Lopac-E-3250
Maxenal
MolPort-001-684-474
Myfedrine
NCGC00015408-01
NCGC00178180-01
NCI60_002955
NINDS_000451
Neodurasina
Neodurasina (TN)
Novafed
PDSP1_001347
PSEUDOEPHEDRINE
Pedia Care
Pseudo
Pseudo 60's
Pseudo-12
Pseudoefedrina
Pseudoefedrina [INN-Spanish]
Pseudoephedrine
Pseudoephedrine (D)
Pseudoephedrine (INN)
Pseudoephedrine D-form
Pseudoephedrine Ephedrine
Pseudoephedrine [INN:BAN]
Pseudoephedrine d-form
Pseudoephedrinum
Pseudoephedrinum [INN-Latin]
Psi-ephedrin
Psi-ephedrine
Robidrine
SPBio_001365
STOCK1N-42675
Spectrum2_001303
Spectrum3_001771
Spectrum4_001162
Spectrum5_000650
Spectrum_000878
Sudafed
Sudafed Decongestant
Sudafed Decongestant 12 Hour
Sudafed Decongestant Extra Strength
Triaminic AM Decongestant Formula
Triaminic Infant Oral Decongestant Drops
UNII-7CUC9DDI9F
alpha-(1-(Methylamino)ethyl)benzyl alcohol
d-Isoephedrine
d-Pseudoephedrine
d-psi-2-Methylamino-1-phenyl-1-propanol
d-psi-Ephedrine
pseudoéphédrine
trans-Ephedrine
ψ-ephedrine
31
Dexamethasoneapproved, investigational, vet_approvedPhase 2208450-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
32Anti-Infective AgentsPhase 1, Phase 221402
33TetrahydrozolinePhase 1, Phase 2593
34Pharmaceutical SolutionsPhase 2, Phase 17793
35Ophthalmic SolutionsPhase 1, Phase 21092
36Adrenergic alpha-AgonistsPhase 1, Phase 21625
37Brimonidine TartratePhase 1, Phase 212270359-46-5
38Adjuvants, ImmunologicPhase 2, Phase 12484
39Adrenergic AgonistsPhase 1, Phase 22877
40Adrenergic alpha-2 Receptor AgonistsPhase 1, Phase 2911
41Adrenergic AgentsPhase 1, Phase 25140
42Central Nervous System DepressantsPhase 212806
43GABA AgentsPhase 21622
44Neurotransmitter AgentsPhase 2, Phase 117734
45AnticonvulsantsPhase 22620
46ProxymetacainePhase 2, Phase 140
47cadexomer iodinePhase 2, Phase 1514
48
IodinePhase 2, Phase 15467553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
49PovidonePhase 2, Phase 1157
50Psychotropic DrugsPhase 26279

Interventional clinical trials:

(show top 50)    (show all 123)
idNameStatusNCT IDPhase
1The Role of Capsular Tension Ring (CTR) in Anterior Capsular ContractionCompletedNCT00717080Phase 4
2Clinical Trial of Lutein for Patients With Retinitis Pigmentosa Receiving Vitamin ACompletedNCT00346333Phase 3
3Randomized Trial for Retinitis PigmentosaCompletedNCT00000116Phase 3
4Randomized Trial of Vitamin A and Vitamin E Supplementation for Retinitis PigmentosaCompletedNCT00000114Phase 3
5The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella BardawilRecruitingNCT01680510Phase 2, Phase 3
6Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of ObesityNot yet recruitingNCT03013543Phase 2, Phase 3
7Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis PigmentosaTerminatedNCT01786395Phase 3
8Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis PigmentosaUnknown statusNCT01914913Phase 1, Phase 2
9Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis PigmentosaCompletedNCT01560715Phase 2
10Trial of Oral Valproic Acid for Retinitis PigmentosaCompletedNCT01233609Phase 2
11A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis PigmentosaCompletedNCT00447993Phase 2
12Safety Study in Retinal Transplantation for Retinitis Pigmentosa.CompletedNCT00345917Phase 2
13A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis PigmentosaCompletedNCT00447980Phase 2
14Effects of Lutein in Retinitis PigmentosaCompletedNCT00029289Phase 1, Phase 2
15Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis PigmentosaCompletedNCT02140164Phase 1, Phase 2
16DHA and X-Linked Retinitis PigmentosaCompletedNCT00100230Phase 2
17An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Retinitis PigmentosaCompletedNCT00661479Phase 1, Phase 2
18Efficacy and Safety of Oral Valproic Acid for Retinitis PigmentosaCompletedNCT01399515Phase 2
19Feasibility Study of a Chronic Retinal Stimulator in Retinitis PigmentosaCompletedNCT00279500Phase 1, Phase 2
20Studying a Potential Protective Effect of L-Dopa on Retinitis PigmentosaRecruitingNCT02837640Phase 2
21Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium BarbarumRecruitingNCT02244996Phase 2
22Safety and Tolerability of hRPC in Retinitis PigmentosaRecruitingNCT02464436Phase 1, Phase 2
23Study of UshStat in Patients With Retinitis Pigmentosa Associated With Usher Syndrome Type 1BRecruitingNCT01505062Phase 1, Phase 2
24RST-001 Phase I/II Trial for Retinitis PigmentosaRecruitingNCT02556736Phase 1, Phase 2
25Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)RecruitingNCT02338973Phase 1, Phase 2
26Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström SyndromeRecruitingNCT02739217Phase 2
27Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) StudyActive, not recruitingNCT02661711Phase 2
28Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for the Treatment of Vision Loss Due to Retinitis PigmentosaActive, not recruitingNCT02086890Phase 1, Phase 2
29A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)Active, not recruitingNCT02110225Phase 1, Phase 2
30Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis PigmentosaActive, not recruitingNCT02320812Phase 1, Phase 2
31Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular EdemaActive, not recruitingNCT02609165Phase 2
32Retinal Imaging of Subjects Implanted With Ciliary Neurotrophic Factor (CNTF)-Releasing Encapsulated Cell Implant for Early-stage Retinitis PigmentosaActive, not recruitingNCT01530659Phase 2
33Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis PigmentosaActive, not recruitingNCT02709876Phase 1, Phase 2
34Argus® II Retinal Stimulation System Feasibility ProtocolActive, not recruitingNCT00407602Phase 2
35Gene Therapy for Blindness Caused by ChoroideremiaActive, not recruitingNCT01461213Phase 1, Phase 2
36Saffron Supplementation in Stargardt's DiseaseActive, not recruitingNCT01278277Phase 1, Phase 2
37Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective StudyEnrolling by invitationNCT02804360Phase 2
38A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1BEnrolling by invitationNCT02065011Phase 1, Phase 2
39The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis PigmentosaNot yet recruitingNCT02018692Phase 1, Phase 2
40Feasibility and Safety of Adult Human Bone Marrow-derived Mesenchymal Stem Cells by Intravitreal Injection in Patients With Retinitis PigmentosaUnknown statusNCT01531348Phase 1
41Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis PigmentosaCompletedNCT01068561Phase 1
42Acupuncture for the Treatment of Vision Loss Due to Retinitis PigmentosaCompletedNCT01604356Phase 1
43Investigating the Effect of Vitamin A Supplementation on Retinitis PigmentosaCompletedNCT00065455Phase 1
44Oral QLT091001 in Retinitis Pigmentosa (RP) Subjects With an Autosomal Dominant Mutation in Retinal Pigment Epithelial 65 Protein (RPE65)CompletedNCT01543906Phase 1
45Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the EyeCompletedNCT00063765Phase 1
46Repeated Treatments of QLT091001 in Subjects With Leber Congenital Amaurosis or Retinitis Pigmentosa (Extension of Study RET IRD 01)CompletedNCT01521793Phase 1
47Safety/Proof of Concept Study of Oral QLT091001 in Subjects With Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) Due to Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT) MutationsCompletedNCT01014052Phase 1
48Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis PigmentosaRecruitingNCT02280135Phase 1
49Retinal Imaging in Patients With Inherited Retinal DegenerationsRecruitingNCT00254605Phase 1
50Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients With Retinal Disease Due to MERTK MutationsRecruitingNCT01482195Phase 1

Search NIH Clinical Center for Cone-Rod Dystrophy

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cone-Rod Dystrophy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Cone-Rod Dystrophy:
Bone marrow-derived stem cells for retinal diseases
Embryonic/Adult Cultured Cells Related to Cone-Rod Dystrophy:
Bone marrow-derived mononuclear cells (family), PMIDs: 23049424, 21225138, 19347139, 23000646

Genetic Tests for Cone-Rod Dystrophy

About this section

Genetic tests related to Cone-Rod Dystrophy:

id Genetic test Affiliating Genes
1 Cone-Rod Dystrophy 227 24 CRX
2 Cone-Rod Dystrophy27 24
3 Tapetoretinal Degeneration27

Anatomical Context for Cone-Rod Dystrophy

About this section

MalaCards organs/tissues related to Cone-Rod Dystrophy:

36
Retina, Eye, Bone, Bone marrow, Liver, Testes

LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cone-Rod Dystrophy:
id TissueAnatomical CompartmentCell Relevance
1 EyeOuter Nuclear LayerMature L Cone Cells Affected by disease
2 EyeOuter Nuclear LayerMature M Cone Cells Affected by disease
3 EyeOuter Nuclear LayerMature M-S Cone Cells Affected by disease
4 EyeOuter Nuclear LayerMature Rod Cells Affected by disease
5 EyeOuter Nuclear LayerMature S Cone Cells Affected by disease

Publications for Cone-Rod Dystrophy

About this section

Articles related to Cone-Rod Dystrophy:

(show top 50)    (show all 193)
idTitleAuthorsYear
1
Retinitis pigmentosa and bilateral cystoid macular oedema in a patient heterozygous for the RIM1 mutation previously associated with cone-rod dystrophy 7. (27176872)
2016
2
Stem Cell-Derived Photoreceptor Transplants Differentially Integrate Into Mouse Models of Cone-Rod Dystrophy. (27367586)
2016
3
Wide-Field Fundus Autofluorescence for Retinitis Pigmentosa and Cone/Cone-Rod Dystrophy. (26427426)
2016
4
Identification of Novel Mutations in the LRR-Cap Domain of C21orf2 in Japanese Patients With Retinitis Pigmentosa and Cone-Rod Dystrophy. (27548899)
2016
5
A novel C8orf37 splice mutation and genotype-phenotype correlation for cone-rod dystrophy. (26865426)
2016
6
Screening of ABCA4 Gene in a Chinese Cohort With Stargardt Disease or Cone-Rod Dystrophy With a Report on 85 Novel Mutations. (26780318)
2016
7
Mizuo-Nakamura phenomenon in cone-rod dystrophy. (27813202)
2016
8
SPATA7: Evolving phenotype from cone-rod dystrophy to retinitis pigmentosa. (26854980)
2016
9
Mutations in CEP78 Cause Cone-Rod Dystrophy and Hearing Loss Associated with Primary-Cilia Defects. (27588451)
2016
10
Molecular genetics of cone-rod dystrophy in Chinese patients: New data from 61 probands and mutation overview of 163 probands. (26992781)
2016
11
GUCY2D mutations in a Chinese cohort with autosomal dominant cone or cone-rod dystrophies. (26298565)
2015
12
Homozygosity mapping and whole-genome sequencing reveals a deep intronic PROM1 mutation causing cone-rod dystrophy by pseudoexon activation. (26153215)
2015
13
Clinical Utility Gene Card for: autosomal recessive cone-rod dystrophy. (25873014)
2015
14
A novel CRX mutation by whole-exome sequencing in an autosomal dominant cone-rod dystrophy pedigree. (26682157)
2015
15
An intronic deletion in the PROM1 gene leads to autosomal recessive cone-rod dystrophy. (26702251)
2015
16
ALMS1 null mutations: a common cause of Leber congenital amaurosis and early-onset severe cone-rod dystrophy. (26010121)
2015
17
Nonsyndromic Early-Onset Cone-Rod Dystrophy and Limb-Girdle Muscular Dystrophy in a Consanguineous Israeli Family are Caused by Two Independent yet Linked Mutations in ALMS1 and DYSF. (26077327)
2015
18
Whole exome sequencing reveals GUCY2D as a major gene associated with cone and cone-rod dystrophy in Israel. (25515582)
2015
19
Next-generation sequencing applied to a large French cone and cone-rod dystrophy cohort: mutation spectrum and new genotype-phenotype correlation. (26103963)
2015
20
Homozygous missense variant in the human CNGA3 channel causes cone-rod dystrophy. (25052312)
2014
21
Mutations in PCYT1A, Encoding a Key Regulator of Phosphatidylcholine Metabolism, Cause Spondylometaphyseal Dysplasia with Cone-Rod Dystrophy. (24387990)
2014
22
Novel Recessive Cone-Rod Dystrophy Caused by POC1B Mutation. (24945461)
2014
23
Disease progression in autosomal dominant cone-rod dystrophy caused by a novel mutation (D100G) in the GUCA1A gene. (24352742)
2014
24
Identification of CNGA3 mutations in 46 families: common cause of achromatopsia and cone-rod dystrophies in Chinese patients. (24903488)
2014
25
Autosomal recessive cone-rod dystrophy associated with compound heterozygous mutations in the EYS gene. (24652164)
2014
26
Pediatric Cone-rod Dystrophy with High Myopia and Nystagmus Suggests Recessive PROM1 Mutations. (24547909)
2014
27
Novel ADAM9 homozygous mutation in a consanguineous Egyptian family with severe cone-rod dystrophy and cataract. (25091951)
2014
28
New Mutations in the RAB28 Gene in 2 Spanish Families With Cone-Rod Dystrophy. (25356532)
2014
29
Mutations in PCYT1A Cause Spondylometaphyseal Dysplasia with Cone-Rod Dystrophy. (24387991)
2014
30
RNA interference gene therapy in dominant retinitis pigmentosa and cone-rod dystrophy mouse models caused by GCAP1 mutations. (24778606)
2014
31
Viral-mediated vision rescue of a novel AIPL1 cone-rod dystrophy model. (25274777)
2014
32
Novel mutations in PCYT1A are responsible for spondylometaphyseal dysplasia with cone-rod dystrophy. (24476460)
2014
33
Disruption of the basal body protein POC1B results in autosomal-recessive cone-rod dystrophy. (25018096)
2014
34
Cone-rod dystrophy caused by a novel homozygous RPE65 mutation in Leber congenital amaurosis. (24771178)
2014
35
Exome sequencing reveals ADAM9 mutations in a child with cone-rod dystrophy. (25546566)
2014
36
GUCY2D- or GUCA1A-related autosomal dominant cone-rod dystrophy: is there a phenotypic difference? (24875811)
2014
37
Exome sequencing of 47 chinese families with cone-rod dystrophy: mutations in 25 known causative genes. (23776498)
2013
38
The Prevalence of Macular Cysts in Patients with Clinical Cone-Rod Dystrophy Determined by Spectral-Domain Optical Coherence Tomography. (23758497)
2013
39
Macular Cysts in Clinical Cone-rod Dystrophy. (24001016)
2013
40
Early detection of central visual function decline in cone-rod dystrophy by the use of macular focal cone electroretinogram. (24008410)
2013
41
Mutations in RAB28, encoding a farnesylated small GTPase, are associated with autosomal-recessive cone-rod dystrophy. (23746546)
2013
42
Screening for variants in 20 genes in 130 unrelated patients with cone-rod dystrophy. (23563732)
2013
43
Successful Gene Therapy in the RPGRIP1-deficient Dog: a Large Model of Cone-Rod Dystrophy. (24091916)
2013
44
Novel GUCA1A mutation identified in a Chinese family with cone-rod dystrophy. (23428504)
2013
45
A novel locus for autosomal dominant cone-rod dystrophy maps to chromosome 10q. (22929024)
2013
46
Phenotypic characterization of a Chinese family with autosomal dominant cone-rod dystrophy related to GUCY2D. (23686677)
2013
47
Childhood Cone-rod Dystrophy with Macular Cystic Degeneration from Recessive CRB1 Mutation. (23767994)
2013
48
A novel large in-frame deletion within the CACNA1F gene associates with a cone-rod dystrophy 3-like phenotype. (24124559)
2013
49
Outer retina analysis by optical coherence tomography in cone-rod dystrophy patients. (23648999)
2013
50
Two siblings with late-onset cone-rod dystrophy and no visible macular degeneration. (24039390)
2013

Variations for Cone-Rod Dystrophy

About this section

UniProtKB/Swiss-Prot genetic disease variations for Cone-Rod Dystrophy:

70
id Symbol AA change Variation ID SNP ID
1CRXp.Arg41TrpVAR_003750rs104894672
2CRXp.Glu80AlaVAR_003751rs28939682
3CRXp.Val242MetVAR_007949rs61748459

Clinvar genetic disease variations for Cone-Rod Dystrophy:

5 (show all 60)
id Gene Variation Type Significance SNP ID Assembly Location
1RHONM_000539.3(RHO): c.403C> T (p.Arg135Trp)SNVPathogenicrs104893775GRCh37Chr 3, 129249760: 129249760
2RHONM_000539.3(RHO): c.44A> G (p.Asn15Ser)SNVPathogenicrs104893786GRCh37Chr 3, 129247620: 129247620
3PDE6BNM_000283.3(PDE6B): c.1669C> T (p.His557Tyr)SNVPathogenicrs121918581GRCh37Chr 4, 655977: 655977
4RPE65NM_000329.2(RPE65): c.1543C> T (p.Arg515Trp)SNVPathogenicrs121917745GRCh37Chr 1, 68895518: 68895518
5PDE6BNM_000283.3(PDE6B): c.1467+1G> CSNVPathogenicrs527236089GRCh37Chr 4, 652807: 652807
6PDE6BNM_000283.3(PDE6B): c.1604T> A (p.Ile535Asn)SNVPathogenicrs527236088GRCh37Chr 4, 654392: 654392
7PRPH2NM_000322.4(PRPH2): c.410G> A (p.Gly137Asp)SNVPathogenicrs527236097GRCh37Chr 6, 42689663: 42689663
8PRPH2NM_000322.4(PRPH2): c.499G> A (p.Gly167Ser)SNVPathogenicrs527236098GRCh37Chr 6, 42689574: 42689574
9ROM1NM_000327.3(ROM1): c.331dupG (p.Leu114Alafs)duplicationPathogenicrs527236104GRCh38Chr 11, 62613612: 62613612
10RHONM_000539.3(RHO): c.520G> A (p.Gly174Ser)SNVPathogenicrs527236103GRCh37Chr 3, 129249877: 129249877
11RHONM_000539.3(RHO): c.562G> A (p.Gly188Arg)SNVPathogenicrs527236100GRCh37Chr 3, 129251125: 129251125
12CRXNM_000554.5(CRX): c.193G> C (p.Asp65His)SNVPathogenicrs527236062GRCh38Chr 19, 47836335: 47836335
13PRCDNM_001077620.2(PRCD): c.2T> C (p.Met1Thr)SNVPathogenicrs527236092GRCh37Chr 17, 74536225: 74536225
14EYSNM_001142800.1(EYS): c.4957dupA (p.Ser1653Lysfs)duplicationPathogenicrs527236065GRCh38Chr 6, 64590910: 64590910
15EYSNM_001142800.1(EYS): c.6557G> A (p.Gly2186Glu)SNVPathogenicrs527236068GRCh37Chr 6, 64791763: 64791763
16EYSNM_001142800.1(EYS): c.7793G> A (p.Gly2598Asp)SNVPathogenicrs527236064GRCh37Chr 6, 64488004: 64488004
17EYSNM_001142800.1(EYS): c.7919G> A (p.Trp2640Ter)SNVPathogenicrs527236066GRCh37Chr 6, 64472506: 64472506
18EYSNM_001142800.1(EYS): c.8805C> A (p.Tyr2935Ter)SNVPathogenicrs527236067GRCh37Chr 6, 64431122: 64431122
19EYSNM_001142800.1(EYS): c.9209T> C (p.Ile3070Thr)SNVPathogenicrs183589498GRCh37Chr 6, 64430718: 64430718
20BEST1NM_004183.3(BEST1): c.763C> T (p.Arg255Trp)SNVPathogenicrs372989281GRCh38Chr 11, 61958194: 61958194
21TOPORSNM_005802.4(TOPORS): c.2554_2557delGAGA (p.Glu852Glnfs)deletionPathogenicrs527236116GRCh37Chr 9, 32541966: 32541969
22SNRNP200NM_014014.4(SNRNP200): c.2042G> A (p.Arg681His)SNVPathogenicrs527236113GRCh37Chr 2, 96958828: 96958828
23SNRNP200NM_014014.4(SNRNP200): c.2047G> T (p.Val683Leu)SNVPathogenicrs527236114GRCh37Chr 2, 96958823: 96958823
24IMPG2NM_016247.3(IMPG2): c.3262C> T (p.Arg1088Ter)SNVPathogenicrs199867882GRCh37Chr 3, 100949961: 100949961
25RDH12NM_152443.2(RDH12): c.776delG (p.Glu260Argfs)deletionPathogenicrs527236099GRCh37Chr 14, 68196025: 68196025
26USH2ANM_206933.2(USH2A): c.10544A> G (p.Asp3515Gly)SNVPathogenicrs527236119GRCh37Chr 1, 215956121: 215956121
27USH2ANM_206933.2(USH2A): c.15233C> G (p.Pro5078Arg)SNVPathogenicrs527236122GRCh37Chr 1, 215807865: 215807865
28USH2ANM_206933.2(USH2A): c.2802T> G (p.Cys934Trp)SNVPathogenicrs201527662GRCh37Chr 1, 216419934: 216419934
29USH2ANM_206933.2(USH2A): c.9751T> C (p.Cys3251Arg)SNVPathogenicrs527236118GRCh37Chr 1, 215972456: 215972456
30PDE6BNM_000283.3(PDE6B): c.2193+1G> ASNVPathogenicrs727504075GRCh37Chr 4, 658734: 658734
31RPGRNM_001034853.1(RPGR): c.2426_2427delAG (p.Glu809Glyfs)deletionPathogenicrs730882261GRCh37Chr X, 38145825: 38145826
32PROM1NM_006017.2(PROM1): c.2077-521A> GSNVPathogenicrs796051882GRCh37Chr 4, 15989860: 15989860
33ABCA4NM_000350.2(ABCA4): c.2927delT (p.Leu976Argfs)deletionPathogenicrs863223338GRCh38Chr 1, 94044736: 94044736
34PDE6BNM_000283.3(PDE6B): c.1060-1G> TSNVPathogenicrs863223339GRCh37Chr 4, 650033: 650033
35RP1NM_006269.1(RP1): c.679T> G (p.Phe227Val)SNVPathogenicrs863223340GRCh37Chr 8, 55534740: 55534740
36IFT140NM_014714.3(IFT140): c.3827G> A (p.Gly1276Glu)SNVPathogenicrs779007169GRCh38Chr 16, 1520177: 1520177
37CRB1NM_001257965.1(CRB1): c.2711G> A (p.Cys904Tyr)SNVPathogenicrs863223341GRCh37Chr 1, 197398685: 197398685
38CRB1NM_001257965.1(CRB1): c.1252dupT (p.Ser418Phefs)duplicationPathogenicrs863223342GRCh38Chr 1, 197421287: 197421287
39PANK2NM_024960.5(PANK2): c.419T> C (p.Phe140Ser)SNVPathogenicrs863223343GRCh38Chr 20, 3912514: 3912514
40C2orf71NM_001029883.2(C2orf71): c.712A> T (p.Lys238Ter)SNVPathogenicrs863223344GRCh37Chr 2, 29296416: 29296416
41RDH12NM_152443.2(RDH12): c.377C> T (p.Ala126Val)SNVPathogenicrs202126574GRCh37Chr 14, 68192801: 68192801
42PDE6BNM_000283.3(PDE6B): c.291C> A (p.Tyr97Ter)SNVLikely pathogenic, Pathogenicrs876657718GRCh37Chr 4, 619706: 619706
43USH2ANM_206933.2(USH2A): c.2299delG (p.Glu767Serfs)deletionPathogenicrs80338903GRCh37Chr 1, 216420437: 216420437
44USH2ANM_206933.2(USH2A): c.2276G> T (p.Cys759Phe)SNVLikely pathogenic, Pathogenicrs80338902GRCh37Chr 1, 216420460: 216420460
45USH2ANM_206933.2(USH2A): c.14020A> G (p.Arg4674Gly)SNVPathogenicrs80338904GRCh37Chr 1, 215844427: 215844427
46RCBTB1NM_018191.3(RCBTB1): c.919G> A (p.Val307Met)SNVLikely pathogenic, Pathogenicrs368217569GRCh37Chr 13, 50123720: 50123720
47RCBTB1NM_018191.3(RCBTB1): c.930G> T (p.Trp310Cys)SNVLikely pathogenic, Pathogenicrs772592456GRCh37Chr 13, 50123709: 50123709
48RCBTB1NM_018191.3(RCBTB1): c.973C> T (p.His325Tyr)SNVLikely pathogenic, Pathogenicrs200826424GRCh37Chr 13, 50123666: 50123666
49RCBTB1NM_018191.3(RCBTB1): c.1164G> T (p.Leu388Phe)SNVLikely pathogenic, Pathogenicrs879255547GRCh37Chr 13, 50118881: 50118881
50USH2ANM_206933.2(USH2A): c.8559-2A> GSNVPathogenicrs397518039GRCh37Chr 1, 216051224: 216051224
51UNC119NM_005148.3(UNC119): c.169A> T (p.Lys57Ter)SNVPathogenicrs267607166GRCh37Chr 17, 26879407: 26879407
52TULP1NM_003322.5(TULP1): c.1145T> C (p.Phe382Ser)SNVPathogenicrs121909076GRCh37Chr 6, 35471593: 35471593
53CRXNM_000554.5(CRX): c.239A> C (p.Glu80Ala)SNVPathogenicrs104894671GRCh37Chr 19, 48339638: 48339638
54CRXCRX, 1-BP DEL, 502GdeletionPathogenicChr na, -1: -1
55CRXNM_000554.5(CRX): c.121C> T (p.Arg41Trp)SNVPathogenicrs104894672GRCh37Chr 19, 48339520: 48339520
56CRXNM_000554.5(CRX): c.122G> A (p.Arg41Gln)SNVPathogenicrs61748436GRCh37Chr 19, 48339521: 48339521
57CRXCRX, 1-BP DEL, 615CdeletionPathogenicChr na, -1: -1
58CRXCRX, 3-BP DEL/2-BP INS, NT816indelPathogenicChr na, -1: -1
59PRPH2NM_000322.4(PRPH2): c.736T> C (p.Trp246Arg)SNVPathogenicrs61755817GRCh37Chr 6, 42672195: 42672195
60RPE65NM_000329.2(RPE65): c.118G> A (p.Gly40Ser)SNVPathogenicrs61751281GRCh37Chr 1, 68912520: 68912520

Copy number variations for Cone-Rod Dystrophy from CNVD:

6
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
134944158454565975118DeletionNPHP4Cone-rod dystrophy
282825141560000023600000Copy numberRPGRIP1Cone-rod dystrophy
383474142082597520889300InsertionRPGRIP1Cone-rod dystrophy
423938683897366139081936DeletionADAM9Cone-rod dystrophy

Expression for genes affiliated with Cone-Rod Dystrophy

About this section
Search GEO for disease gene expression data for Cone-Rod Dystrophy.

Pathways for genes affiliated with Cone-Rod Dystrophy

About this section

GO Terms for genes affiliated with Cone-Rod Dystrophy

About this section

Cellular components related to Cone-Rod Dystrophy according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ciliary basal bodyGO:003606410.9RPGR, TOPORS, USH2A
2photoreceptor disc membraneGO:009738110.9ABCA4, PDE6B, RHO
3photoreceptor inner segment membraneGO:006034210.9RDH12, RHO
4photoreceptor connecting ciliumGO:003239110.8RP1, TOPORS, USH2A
5photoreceptor inner segmentGO:000191710.7C2orf71, RHO, RP1, TULP1, USH2A
6photoreceptor outer segmentGO:000175010.4ABCA4, C2orf71, PROM1, PRPH2, RHO, RP1
7photoreceptor outer segment membraneGO:004262210.3PROM1, RHO, ROM1

Biological processes related to Cone-Rod Dystrophy according to GeneCards Suite gene sharing:

(show all 20)
idNameGO IDScoreTop Affiliating Genes
1phototransductionGO:000760211.1RHO, UNC119
2eye photoreceptor cell developmentGO:004246211.1CRB1, TULP1
3detection of light stimulusGO:000958311.1PDE6B, RHO
4camera-type eye photoreceptor cell differentiationGO:006021911.1PROM1, ROM1
5regulation of rhodopsin mediated signaling pathwayGO:002240011.1PDE6B, RHO
6protein localization to photoreceptor outer segmentGO:190354611.1C2orf71, TULP1
7detection of light stimulus involved in visual perceptionGO:005090811.0BEST1, EYS, TULP1
8retina morphogenesis in camera-type eyeGO:006004211.0PROM1, ROM1
9retina layer formationGO:001084211.0PROM1, TOPORS
10photoreceptor cell outer segment organizationGO:003584511.0C2orf71, RP1, TOPORS
11rhodopsin mediated signaling pathwayGO:001605611.0PDE6B, RHO
12phototransduction, visible lightGO:000760311.0ABCA4, PDE6B, RHO, RP1
13retinal cone cell developmentGO:004654911.0RP1, TOPORS
14retinal rod cell developmentGO:004654810.9RP1, TOPORS
15sensory perception of light stimulusGO:005095310.9RHO, USH2A
16retinoid metabolic processGO:000152310.9ABCA4, RDH12, RHO
17retina development in camera-type eyeGO:006004110.8PDE6B, PRPH2, RHO, RP1, TULP1
18photoreceptor cell maintenanceGO:004549410.8ABCA4, PROM1, RDH12, RHO, RP1, TULP1
19response to stimulusGO:005089610.8C2orf71, CRX, PRCD, RDH12, RPGR, USH2A
20visual perceptionGO:00076019.7ABCA4, BEST1, C2orf71, CRX, PDE6B, PRCD

Sources for Cone-Rod Dystrophy

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet